Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Total Non-Current Liabilities: 2020-2024

Historic Total Non-Current Liabilities for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Dec 2024 value amounting to $190.8 million.

  • Arcutis Biotherapeutics' Total Non-Current Liabilities fell 24.17% to $212.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $212.5 million, marking a year-over-year decrease of 24.17%. This contributed to the annual value of $190.8 million for FY2024, which is 24.25% down from last year.
  • According to the latest figures from FY2024, Arcutis Biotherapeutics' Total Non-Current Liabilities is $190.8 million, which was down 24.25% from $251.8 million recorded in FY2023.
  • In the past 5 years, Arcutis Biotherapeutics' Total Non-Current Liabilities registered a high of $251.8 million during FY2023, and its lowest value of $27.6 million during FY2020.
  • Over the past 2 years, Arcutis Biotherapeutics' median Total Non-Current Liabilities value was $221.3 million (recorded in 2023), while the average stood at $221.3 million.
  • Per our database at Business Quant, Arcutis Biotherapeutics' Total Non-Current Liabilities skyrocketed by 300.67% in 2021 and then decreased by 24.25% in 2024.
  • Over the past 4 years, Arcutis Biotherapeutics' Total Non-Current Liabilities (Yearly) stood at $27.6 million in 2020, then spiked by 300.67% to $110.5 million in 2021, then reached $251.8 million in 2023, then dropped by 24.25% to $190.8 million in 2024.